Clinical Decision-Making in Unprovoked vs Provoked Pulmonary Embolism
In an episode of the Oncology Brothers podcast, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, spoke with Jennifer Vaughn, MD, and Nicolas Gallastegui Crestani, MD, both of The Ohio State University, about the complexities of venous thromboembolism (VTE).
The experts reviewed two challenging cases in young, fit patients—one involving unprovoked pulmonary embolism (PE) and another involving provoked PE.
Management of Unprovoked PE
The first case discussed a 34-year-old man with shortness of breath and lower extremity swelling who had an unprovoked PE. In a young, healthy patient with no clear provoking risk factors, Dr. Vaughn’s initial concern is a high risk of VTE recurrence. While a hypercoagulable workup may identify inherited risk factors, she emphasized that these results rarely change the long-term management plan in this patient population.
Dr. Gallastegui Crestani agreed, describing this as a classic presentation associated with a significant recurrence risk—approximately 30% over 10 years. He often recommends long-term anticoagulation.
Furthermore, he explained that hypercoagulability testing is reserved for situations in which a patient wants to discontinue anticoagulation. When testing is pursued, lupus anticoagulant, protein C activity, and antithrombin are the most clinically meaningful evaluations, Dr. Gallastegui Crestani said. He also stressed the importance of completing an initial 6 months of full-dose anticoagulation before reassessing whether dose reduction or continuation is appropriate.
Dr. Vaughn described using validated risk scores selectively. Determining whether an event is provoked or unprovoked is central to decision-making, although many risk factors fall into a gray zone, she explained. For patients with major transient risk factors such as surgery or prolonged immobility, stopping anticoagulation after completing therapy is reasonable, she explained. In patients with minor risk factors, tools such as D-dimer testing may be beneficial when assessing residual risk if anticoagulation is discontinued.
For follow-up evaluation, Dr. Vaughn shared that she does not routinely use CT angiography, and only uses lower extremity Dopplers in rare circumstances.
Drs. Vaughn and Gallastegui Crestani said echocardiography plays an important role in practice. An echocardiogram is performed in every patient at initial presentation within Dr. Gallastegui Crestani’s practice, and he tries to reassess within the first 3 months.
“We always tell patients clots are like dinosaurs. They die and disappear from the face of earth or they become fossils,” Dr. Gallastegui Crestani said.
Both experts explained that unprovoked DVT or PE warrants long-term anticoagulation, often at a reduced dose after the initial treatment phase, while provoked events can be managed with 3 to 6 months of therapy.
Cancer-Associated Thrombosis
In the second case, the experts discussed a 43-year-old woman with newly diagnosed stage III breast cancer who developed a PE shortly before starting neoadjuvant chemotherapy.
In this setting, Dr. Vaughn said that malignancy should be considered the primary driver of thrombosis. She counsels patients that if cancer is present or treatment is ongoing, anticoagulation is required. Anticoagulation is usually continued throughout the patient’s cancer treatment and for at least 3 months after completion. At that point, restaging scans help determine whether anticoagulation can be safely discontinued.
However, for patients with metastatic disease, anticoagulation is continued indefinitely, if the risk doesn’t outweigh benefit, Dr. Vaughn said.
Dr. Gallastegui Crestani added that anticoagulation should typically not be interrupted during the first month following a cancer-associated VTE except in emergencies. In those cases, inferior vena cava filters may be used.
Beyond the first month, he explained that he may consider discontinuing anticoagulation. He also considers whether a patient will undergo a surgical procedure. Dr. Gallastegui Crestani said he will briefly hold anticoagulation but resume when it’s clinically safe.